Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted th

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock

Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three

Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or

A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics,

Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increa

The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strateg

The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strateg

SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-s

• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final ac

• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final ac

Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed with

SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical

Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) was the recipient of a significant increase in

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targe

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targe

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targe

All required regulatory approvals secured for trial site onboarding and patient enrollment at three

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) fell 0.3% during mid-day trading on

Oragenics, Inc. (NYSE:OGEN) ("the "Company") a clinical-stage biotechnology company deve

Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mT

Oragenics, Inc. (NYSE American: OGEN) ("the "Company"), a clinical-stage biotechnology c

Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for

Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Tre

Oragenics (AMEX:OGEN) reported quarterly losses of $(1.96) per share. This is a 82.69 percent increa

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targe

Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug deliv

Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-re

Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for

Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapie